INDSWFTLABInd-Swift Laboratories Limited
Convert to ideaHealthcare · Pharmaceuticals
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeUp 0.3 this quarter.
Momentum from moving averages, Supertrend and RSI.
4 forensic issues found. Sign in to see which.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
4 found · risk elevated
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹240 Cr | ₹34 Cr | 15.67% | 14.23% | ₹3.94 | 33.6x |
| Q1 FY2027 | ₹191 Cr | ₹25 Cr | 13.50% | 12.89% | ₹2.84 | 47.5x |
| Q4 FY2026 | ₹170 Cr | ₹15 Cr | 7.34% | 8.90% | ₹1.81 | N/A |
| Q3 FY2026 | ₹149 Cr | ₹11 Cr | -2.30% | 7.18% | ₹1.32 | 27.3x |
| Q2 FY2026 | ₹150 Cr | ₹9 Cr | -3.18% | 5.82% | ₹1.10 | 6.5x |
| Q1 FY2026 | ₹148 Cr | ₹8 Cr | -2.44% | 5.48% | ₹1.18 | 9.5x |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Pharmaceuticals
Compare with peers →Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.